Indications
Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.
Composition
- Active substance
- dacomitinib monohydrate
- International name (INN)
- dacomitinib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vizimpro
- Active substance
- dacomitinib monohydrate
- ATC code
- L01EB07
- Therapeutic area
- Carcinoma, Non-Small-Cell Lung
- Marketing authorisation holder